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Background:  The human Rho guanine nucleotide exchange factor 11 (ARHGEF11) functions as an activator of Rho GTPases 
and is thought to influence insulin signaling. The R1467H variant of ARHGEF11 has been reported to be associated with suscep-
tibility to type 2 diabetes mellitus (T2DM) in Western populations. 
Methods:  We investigated the effects of the R1467H variant on susceptibility to T2DM as well as related traits in a Korean popu-
lation. We genotyped the R1467H (rs945508) of ARHGEF11 in 689 unrelated T2DM patients and 249 non-diabetic individuals 
and compared the clinical and biochemical characteristics according to different alleles.
Results:  The H allele was significantly more frequent in T2DM cases than in controls (P = 0.037, 17.1% and 13.1%; respectively). 
H homozygocity was associated with a higher risk of T2DM compared to those with R/R or R/H genotype (odds ratio, 5.24; 95% 
confidence interval, 1.06 to 25.83; P = 0.042). The fasting plasma glucose, HbA1c, fasting insulin, HOMA2-IR and HOMA2-%β 
levels did not differ significantly between different genotypes. 
Conclusion:  Our study replicated associations of the ARHGEF11 polymorphism with increased risk of T2DM in a Korean pop-
ulation and thus supports previous data implicating a potential role of ARHGEF11 in the etiology of T2DM. Further studies re-
vealing the underlying mechanism for this association are needed.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a multi-factorial trait, in 
which individual risk is defined by the complex interplay of 
genetic and environmental factors [1-3]. To search for genetic 
loci that contribute to T2DM, several genomic linkage scans 
have been completed worldwide [4,5]. Several previous stud-
ies have reported evidence for linkage between T2DM and the 
chromosome 1q21-q24 region [6-8] and have also reported that 
this region contributes to impaired glucose tolerance (IGT) [9]. 
In the Pima Indians and Amish populations, investigators gen-
otyped multiple single nucleotide polymorphisms (SNPs) with-
in this region, and results pointed to a region including the Rho 
guanine nucleotide exchange factor 11 (ARHGEF11) gene 
[10,11]. ARHGEF11 is an activator of Rho GTPases and may 
play a role in the G protein signaling involved in β-cell apop-
tosis, insulin secretion and insulin signaling. ARHGEF11 is ex-
pressed in the pancreas, liver, muscle, and adipose tissue [12-
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14]. Previous studies have implicated Rho subfamily G pro-
teins in physiological insulin secretion [13,14], and Rho GT-
Pases have been suggested to play a role in insulin signaling 
through the activation of p38 mitogen activated protein kinase 
and Jun NH2-terminal kinase pathways [15-17]. Moreover, 
Rho family small GTP-binding protein TC10 activation and 
phosphatidylinositol 3-kinase activation regulates the dynam-
ic actin rearrangement required for insulin-stimulated trans-
location of GLUT4 [18,19]. Together, these data suggest that 
proteins involved in G protein signaling, such as ARHGEF11, 
may play an important role in glucose homeostasis.
  The full-length ARHGEF11 protein contains 1,522 amino 
acids, has a calculated molecular mass of 168.6 kD and includes 
41 exons [20]. The C-terminal (amino acids 1,181–1,522) re-
gion of ARHGEF11 protein has been shown to regulate ARH-
GEF11 protein activity [21]. Recently, a non-synonymous 
amino acid substitution variant within the C-terminal region 
of ARHGEF11 R1467H (rs945508, G/A), was reported to be 
associated with T2DM in Western sample populations [11, 
22,23]. In the Amish, the 1467R allele was the risk allele for 
T2DM, while the 1467H allele was the risk allele for insulin re-
sistance and T2DM in Pima Indians [11,22]. Moreover, repli-
cated association of the 1467H allele as the risk allele for 
T2DM and/or IGT in a German Caucasian population have 
been reported [23]. This inconsistency in the effects of genetic 
variants may be due to different genetic backgrounds between 
the different ethnic groups. Therefore, in the present study, we 
evaluated the effects of this variant on the susceptibility to 
T2DM as well as its relation to metabolic parameters in a Ko-
rean population. 
METHODS
Study subjects
A total of 689 unrelated T2DM patients and 249 non-diabetic 
individuals were recruited at the Inha University Hospital of 
Korea from April 2004 to December 2007. Diabetes was defined 
according to the 1997 American Diabetes Association diagnos-
tic criteria [24]. Exclusion criteria were type 1 diabetes mellitus, 
current malignancy, history of ketoacidosis, positive for glu-
tamic acid decarboxylase antibody, severe kidney or liver dis-
ease, and corticosteroid use. All subjects gave written informed 
consent before taking part in the study, which was approved 
by the Inha University Hospital Institutional Review Board. 
Single nucleotide polymorphism genotyping 
Genomic DNA was extracted from leukocytes in the whole-
blood samples using a Gentra Puregene Blood Kit Plus (Qia-
gen, Valencia, CA, USA). Genotyping of the R1467H was 
achieved using the TaqMan allelic discrimination assay (Ap-
plied Biosystems, Foster City, CA, USA). To assess genotyping 
reproducibility, a random -10% selection of the samples was 
re-genotyped in all SNPs with 100% concordance. The SNPs 
were in accordance with Hardy–Weinberg equilibrium in the 
T2DM subjects (P > 0.10) and in the control subjects (P > 0.20).
Clinical and biochemical measurements 
Baseline laboratory data and anthropometric measurements 
were collected for each patient. Low density lipoprotein cho-
lesterol levels were calculated using the Friedewald formula 
[25], and plasma glucose was measured using a glucose oxi-
dase method. Hemoglobin A1c (HbA1c) values were deter-
mined using high-performance liquid chromatography, and 
insulin concentrations were measured using a radioimmuno-
assay kit (IRMA kit; DAINABOT, Tokyo, Japan). The insulin 
resistance and insulin secretion indexes were calculated using 
the HOMA2 model (HOMA2-IR and HOMA2-%β, respec-
tively), i.e., the updated computer model for the pairing of fast-
ing plasma glucose and insulin (The HOMA2 model is avail-
able from www.ocdem.ox.ac.uk) [26]. 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows 
version 18.0 (SPSS Inc., Chicago, IL, USA), and data are shown 
as means ± standard deviation, unless otherwise indicated. 
Associations between categorical variables were analyzed us-
ing χ
2 tests and continuous variables were assessed using Stu-
dent’s t-test. The differences in allelic and genotypic frequen-
cies between the diabetic and control individuals were analyzed 
using Pearson’s χ
2 test. Fasting insulin, HOMA2-IR and 
HOMA2-%β variables were log-transformed to correct for 
skew. The odds ratio (OR) was assessed by counting the num-
ber of risk alleles for each individual, and association of geno-
types with T2DM was assessed via a logistic regression analy-
sis adjusted for age, gender, and body mass index (BMI). All P 
< 0.05 were considered to be significant. 
RESULTS
We performed a case–control study including 249 non-diabet-370
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ic individuals and 689 unrelated T2DM patients in Korea. The 
group of patients with T2DM included 383 men and 306 wom-
en, and the control group included 128 men and 121 women 
(P = 0.256). Non-diabetic individuals were older than T2DM 
patients (P < 0.001, 63.25 ± 7.12, 52.23 ± 9.70 years, respective-
ly) and had a lower BMI 23.59 ± 2.89 kg/m² (P < 0.001, 25.21 
± 3.87 kg/m²). The clinical features of the participants are sum-
marized in Table 1. Allelic and genotypic frequencies of the 
SNP in ARHGEF11 are shown in Table 2. The H allele was sig-
nificantly more frequent in T2DM cases than in controls (17.1% 
in T2DM vs. 13.1% in control group, P = 0.037). Genotypic 
frequencies were significantly different in T2DM patients com-
pared to those of the controls (P = 0.040, R/R 479 [69.5%] vs. 
186 [74.7%], R/H 184 [26.7%] vs. 61 [24.5%], H/H 26 [3.8%] 
vs. 2 [0.8%], respectively). Moreover, in patients with T2DM, 
the probability of having the H/H genotype vs. R/R + H/H was 
significantly higher compared to that of the control subjects (P 
= 0.018, 3.8% vs. 0.8%), and this association was significant af-
ter adjustment for age, gender and BMI (OR, 5.24; 95% confi-
dence intervals [CI], 1.06–25.83; P = 0.042). The odds ratio es-
timates along with 95% CI values for the ARHGEF11 R1467H 
allele in various studies conducted in T2DM patients are pre-
sented in Table 3. In order to further examine the role of the H 
allele in T2DM subjects, we assessed whether the H homozy-
gote was associated with insulin secretion or insulin resistance 
in T2DM subjects. There was no significant difference between 
R/R or R/H subjects and H/H subjects with regard to fasting 
plasma glucose, HbA1c, fasting insulin, HOMA2-IR or 
HOMA2-%β (P > 0.05, Table 4).
Table 1.  Clinical characteristics of the study population
T2DM 
(n = 689)
Control 
(n = 249)
P value
Gender, M/F 383/306 128/121 0.256
Age, yr 52.2 ± 9.7 63.3 ± 7.1 < 0.001
Age at onset of diabetes, yr 46.1 ± 9.4 NA NA
BMI, kg/m
2 25.2 ± 3.9 23.6 ± 2.9 < 0.001
Fasting plasma glucose, mmol/L 8.1 ± 2.8 5.0 ± 0.7 < 0.001
Triglyceride, mmol/L  1.8 ± 1.2 1.3 ± 0.8 < 0.001
Total cholesterol, mmol/L 4.8 ± 1.1 5.0 ± 0.9 0.034
LDL-C, mmol/L 2.8 ± 1.0 3.0± 0.9 < 0.001
Glucose-lowering medications NA NA
No glucose-lowering agents 247 (35.8) NA NA
Oral anti-diabetic drugs  380 (55.2) NA NA
  Insulin 98 (14.2) NA NA
Values are presented as means ± standard deviation or number (%) 
unless otherwise indicated. 
T2DM, type 2 diabetes mellitus; BMI, body mass index; LDL-C, low 
density lipoprotein cholesterol; NA, not applicable.
Table 2.  Allelic and genotypic distributions of the R1467H 
variant in T2DM and control subjects 
T2DM
(n = 689)
Control
(n = 249)
 P value
R1467H Allele 0.037
(39 Exon) R 1,142 (82.9) 433 (86.9)
H 236 (17.1) 65 (13.1)
Genotype 0.040 
R/R 479 (69.5) 186 (74.7)
R/H 184 (26.7) 61 (24.5)
H/H 26 (3.8) 2 (0.8)
Recessive model 0.018 
R/R+R/H 663 (96.2) 247 (99.2)
H/H 26 (3.8) 2 (0.8)
Values are presented as number (%).
Recessive model: wild homozygote genotype vs. (risk homozygote 
genotype + heterozygote genotype).
T2DM, type 2 diabetes mellitus.
Table 3.  Odds ratio estimates with confidence intervals of the R1467H variant in multiple ethnic populations
Minor allele 
frequency, %
T2DM T2DM/IGT
Reference
No. P value OR (95% CI)
a No. P value OR (95% CI)
a
Korean  13.0  689 0.042 5.24 (1.06 to 25.83)
Pima Indian  10.0  524 0.030 5.09 (1.20 to 21.55) [10]
Old Order Amish 47.0  145 0.040 0.66 (0.44 to 0.98) 438 0.170 0.81 (0.59 to 1.10) [11]
German Caucasian  46.0  685 0.004 1.43 (1.12 to 1.87) 758 0.001 1.46 (1.16 to 1.82) [23]
T2DM, type 2 diabetes mellitus; IGT, impaired glucose tolerance; OR, odds ratio; CI, confidence interval.
aAnalysis of the association of the R1467H variant with patients was calculated using an additive model under a logistic regression model after 
adjusting for age, gender, and body mass index. 371
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DISCUSSION
In this study, we found a significant association between the 
variation at R1467H in ARHGEF11 and T2DM in a Korean 
population, similar to the results previously reported in Pima 
Indians and German Caucasians [10,23]. It is noteworthy that 
the allele frequency and odds ratio in our study are closer to 
those in Pima Indians (Table 3) and that the association be-
tween the variation at R1467H in ARHGEF11 and T2DM 
which has been observed in other ethnic groups has been rep-
licated, supporting the reliabilities of both previous studies as 
well as that of our present study. However, the association with 
type 2 diabetes may have a stronger impact in the German Cau-
casians than in Koreans due to the higher frequency of the 
R1467H risk allele (H) in German Caucasians (46% vs. 13%). 
The lower allelic frequency in Koreans is similar to the data re-
ported by the HapMap project [27]. A different association of 
the common R allele with T2DM was shown in a study of the 
Amish [11]. This may be due to population differences; how-
ever, considering the Swiss–German ancestry of the Amish, it 
was surprising that data from German Caucasians more close-
ly adhered to the Pima findings rather than those reported in 
the Amish. Although, there is no evidence that the R1467H 
variant may exert an effect on ARHGEF11 expression, an Arg 
to His amino acid change in the C-terminal region of ARH-
GEF11 may be brought about by the variant. Thus, we believe 
that our present findings are consistent with those found in 
Pima Indians and German Caucasians, strongly suggesting the 
role of the variant in the pathophysiology of T2DM.
  The H allele at R1467H in ARHGEF11 increases the risk for 
T2DM in Pima Indians by reducing insulin-stimulated glucose 
uptake. Among the non-diabetic, full-heritage Pima Indians, 
subjects with an H allele had a lower mean glucose disposal 
rate during a hyperinsulinemic-euglycemic clamp. To further 
illuminate the role of the H allele in a population of Korean 
T2DM patients, related traits were compared in subjects with 
H/H homozygocity and in those carrying the major R allele 
(R/H or R/R). Our study did not reveal any significant differ-
ences in fasting plasma glucose, HbA1c, fasting insulin, 
HOMA2-IR and HOMA2-%β levels in T2DM subjects be-
tween the two groups. The H allele also did not increase fast-
ing plasma glucose in the control patients, possibly due to the 
various drug effects experienced by T2DM patients or that the 
HOMA parameters are a relatively crude analysis method 
compared to the clamp method [28]. It may also be due to dif-
ferent ethnic and environmental backgrounds. Therefore, ad-
ditional investigations in independent populations, as well as 
functional studies, will be necessary to clarify the influence of 
the ARHGEF11 variant on T2DM. There is also a possibility 
that the R1467H variant may not be the true functional vari-
ant but rather a variant in linkage disequilibrium with the true 
functional variant. 
  This study had several limitations. First, our study was simi-
lar to others in Pima Indians and had similar associations be-
tween the variations at R1467H in ARHGEF11 and T2DM but 
could not determine a significant association between the R/
Table 4.  Clinical and biochemical characteristics between R/R+R/H and H/H genotypes of ARHGEF11
T2DM 
P value
Control
P value
R/R+R/H H/H R/R+R/H  H/H
Gender, M/F 368/295 15/11 0.826  128/119 0/2 0.144 
Age, yr 52.2 ± 9.7 52.5 ± 8.8 0.447  63.2 ± 7.1 66.0 ± 11.3 0.584 
BMI, kg/m² 25.2 ± 3.9 24.8 ± 2.9 0.630  23.6 ± 2.9 20.9 ± 1.3 0.185 
Fasting plasma glucose, mmol/L 8.2 ± 2.8 8.1 ± 3.0 0.675  5.0 ± 0.7 3.7 ± 0.5 0.007 
HbA1c, % 7.9 ± 2.9 7.7 ± 1.6 0.895  5.6 ± 0.3 5.5 ± 0.2 0.530
log 10 [fasting insulin, mIU/mL]
a 1.76 ± 0.29 1.72 ± 0.20 0.561
log 10 [HOMA2-%β]
a 1.66 ± 0.28 1.67 ± 0.25 0.353 
log 10 [HOMA2-IR]
a 0.37 ± 0.14 0.34 ± 0.09 0.149 
Data are means ± standard deviation unless otherwise indicated. Associations between categorical variables were analyzed using χ
2 tests and 
continuous variables were assessed using Student’s t-test.  
T2DM, type 2 diabetes mellitus; BMI, body mass index.
aFasting insulin, HOMA2-IR and HOMA2-%β variables were log-transformed to correct for skew. In the R/R+R/H and H/H groups, fasting 
insulin, HOMA2-IR and HOMA2-%β measurements were available for only 534 and 21 patients, respectively.372
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R+R/H and H/H groups of T2DM with regard to fasting plas-
ma glucose, HbA1c, fasting insulin, HOMA2-IR or HOMA2-
%β level. In Pima Indians, the investigator demonstrated that 
the H allele at R1467H in ARHGEF11 increases the risk of 
T2DM by reducing insulin-stimulated glucose uptake in non-
diabetic controls. However, our study did not measure insulin 
levels in non-diabetic control subjects. Second, we used fast-
ing insulin concentration and the HOMA2 model as markers 
of insulin resistance. The HOMA2 model has been significantly 
correlated with the hyperinsulinemic-euglycemic clamp, which 
is accepted as the standard in defining insulin resistance; how-
ever, the HOMA2 model is described for approximate estima-
tion [28]. Finally, because our study was conducted in a Kore-
an population, we cannot generalize these findings to other 
ethnic groups.
  In conclusion, our study replicated associations of the AR-
HGEF11 polymorphism with increased risk of T2DM in a Ko-
rean population and thus supports previous data implicating a 
potential role of ARHGEF11 in the etiology of T2DM. Further 
replication studies in different ethnic populations are neces-
sary to confirm the effect of the R1467H variant on T2DM.
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